29-01-2018
designer491 / iStockphoto.com
Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, Ablynx, pharmaceutical merger, mergers and acquisitions, blood disorder, nanobody, biotech medicine, caplacizumab, thrombotic thrombocytopenic
Allele Biotech partners with Scientist.com to develop nanoantibodies
05-12-2018
Sanofi in talks to sell generics unit for €1.9bn
19-04-2018
Seattle Genetics to acquire biotech company for $614m
02-02-2018
Celgene reveals plans to acquire Juno for $9bn
23-01-2018
Sanofi to buy Bioverativ for $11.6bn
23-01-2018
